The CNS disease therapy developer raised a further $20m, adding to a $45m close in April that included GV and Takeda Ventures.
US-based brain disease treatment developer Cerevance added $20m yesterday to increase a series B round featuring pharmaceutical firm Takeda and internet and technology group Alphabet to $65m.
UPMC Enterprises, the commercialisation arm of University of Pittsburgh Medical Center, provided the extra funding along with Dolby Family Ventures, Foresite Capital and Casdin Capital.
The April 2020 first close featured Alphabet subsidiary GV and Takeda investment vehicle Takeda Ventures in addition to Foresite Capital, Lightstone Ventures, Bill Gates and Dementia Discovery…